A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion

作者：Chiazza Fausto; Chegaev Konstantin; Rogazzo Mara; Cutrin Juan C; Benetti Elisa; Lazzarato Loretta; Fruttero Roberta; Collino Massimo^*

来源：Oxidative Medicine and Cellular Longevity, 2015, 2015: 804659.

DOI：10.1155/2015/804659

Edaravone (5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one, EDV) is a free-radical scavenger reduces organ ischemic injury. Here we investigated whether the protective effects of EDV in renal ischemia/reperfusion (I/R) injury may be enhanced by an EDV derivative bearing a nitric oxide-(NO-) donor furoxan moiety (NO-EDV). Male Wistar rats were subjected to renal ischemia (45 minutes), followed by reperfusion (6 hours). Administration of either EDV (1.2-6-30 mu mol/kg, i.v.) or NO-EDV (0.3-1.2-6 mu mol/kg, i.v.) dose-dependently attenuated markers of renal dysserum urea and creatinine, creatinine clearance, urine flow, urinary N-acetyl-beta-D-glucosaminidase, and neutrophil gelatinase-associated lipocalin/lipocalin-2). NO-EDV exerted protective effects in the dose-range 1.2-6 mu mol/kg, while a higher dose (30 mu mol/kg) was needed to obtain protection by EDV. Both EDV and NO-EDV modulated tissue markers of oxidative stress and lipid peroxidation. NO-EDV, but not EDV, activated endothelial NO synthase (NOS) and blunted I/R-induced upregulation of inducible NOS, secondary to modulation of Akt and NF-kappa B activation, respectively. Besides NO-EDV administration inhibited I/R-induced IL-1 beta, IL-18, IL-6, and TNF-alpha overproduction. Overall, these findings demonstrate that the NO-donor moiety contributes to the protection against early renal I/R injury and suggest that NO-donor EDV codrugs are worthy of additional study as innovative pharmacological tools.

• 出版日期2015